



**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**  
*NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.*  
Tuesday, April 21, 2026  
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
<p><b>Microsoft Teams</b></p> <p><a href="#">Join the meeting now</a></p> <p>Meeting ID: 225 956 973 145 06</p> <p>Passcode: hg9By9ZV</p> <p><a href="#">Download Teams</a>   <a href="#">Join on the web</a></p>	<p>+1 858-252-2734 (United States)</p> <p>Phone conference ID: 718 536 178#</p>

**AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session (Upon Request)**
- III. Old Business**
  - a. Approval of July 2025 Meeting Minutes
  - b. Approval of October 2025 Meeting Minutes
  - c. Approval of January 2026 Meeting Minutes
  - d. Presentation of Itvisma® (onasemnogene abeparovvec-brve) Clinical Criteria
- IV. New Business**
  - a. New Products to Market to be Reviewed as Single Products
    - i. Palsonify™ (paltusotine) – Non-PDL
    - ii. Voyxact® (sibeprenlimab-szsi) – Non-PDL
    - iii. Attruby™ (acoramidis) – Non-PDL
    - iv. Redemplo® (plozasiran) – Non-PDL
    - v. Forzinity™ (elamipretide) – Non-PDL
    - vi. Aqvesme™ (mitapivat) – Non-PDL
    - vii. Pivya (pivmecillinam) – Non-PDL
    - viii. Zycubo® (copper histidinate) – Non-PDL
    - ix. Cardamyst™ (etripamil) – Non-PDL
    - x. Myqorzo™ (aficamten) – Non-PDL
- V. Therapeutic Classes with Recommended PDL Status Changes**
  - a. Bone Resorption Suppression and Related Agents
  - b. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
  - c. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists





**VI. Therapeutic Classes with Recommended Structure Changes (No PDL Status Changes)**

- a. Colony Stimulating Factors
- b. Steroids, Topical

**VII. Consent Agenda**

- a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

<ul style="list-style-type: none"> <li>• Narcotic Agonist/Antagonists</li> <li>• Narcotics, Fentanyl Buccal Products</li> <li>• Narcotics, Long-Acting</li> <li>• Narcotics, Short-Acting</li> <li>• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</li> <li>• Opiate Dependence Treatments</li> <li>• Antihyperuricemics</li> <li>• Erythropoiesis Stimulating Proteins</li> <li>• Phosphate Binders</li> <li>• Sickle Cell Anemia Treatments</li> <li>• Thrombopoiesis Stimulating Proteins</li> <li>• Alpha-Glucosidase Inhibitors</li> <li>• Insulins and Related Agents</li> </ul>	<ul style="list-style-type: none"> <li>• Meglitinides</li> <li>• Metformins</li> <li>• Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors</li> <li>• Sulfonylureas</li> <li>• Thiazolidinediones (TZDs)</li> <li>• Androgenic Agents</li> <li>• Glucagon Agents</li> <li>• Growth Hormone</li> <li>• Pancreatic Enzymes</li> <li>• Progestins for Cachexia</li> <li>• Steroids, Oral</li> <li>• Uterine Disorder Treatments</li> </ul>
---	--

**VIII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. July 28, 2026 (Note: Date Change)
  - ii. October 13, 2026

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.

